Subsequent Event	9 Months Ended
Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Event	16. Subsequent Event On October 1, 2019, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with accredited investors (the “Investors”), pursuant to which the Company issued and sold to the Investors in a private placement an aggregate of 7,647,057 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a price of $8.50 per share (the “Offering”). The Offering closed on October 3, 2019. The Company received aggregate gross proceeds of approximately $65.0 million, before deducting offering expenses of $0.1 million. The Company intends to use the net proceeds to fund research and development expenses, including the clinical development of CPI-0610, CPI-1205 and CPI-0209, to advance the current pipeline of preclinical candidates, to discover and develop additional preclinical product candidates using its platform, as well as for working capital and other general corporate purposes.

Subsequent Event

9 Months Ended

Sep. 30, 2019

16. Subsequent Event

On October 1, 2019, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with accredited investors (the “Investors”), pursuant to which the Company issued and sold to the Investors in a private placement an aggregate of 7,647,057 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a price of $8.50 per share (the “Offering”). The Offering closed on October 3, 2019.

The Company received aggregate gross proceeds of approximately $65.0 million, before deducting offering expenses of $0.1 million. The Company intends to use the net proceeds to fund research and development expenses, including the clinical development of CPI-0610, CPI-1205 and CPI-0209, to advance the current pipeline of preclinical candidates, to discover and develop additional preclinical product candidates using its platform, as well as for working capital and other general corporate purposes.